B+
Bull case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
DTIL
Precision BioSciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+74.2
Score
AI commentary
Recent company and SEC coverage is constructive on clinical progress, recruitment, and runway, but the evidence is primarily filing-driven. Q2 revenue/EPS surprise versus consensus and post-print analyst revisions are unavailable, so the earnings follow-up remains a cautious monitoring view rather than a validated bullish consensus thesis.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventQ2 update strengthens HBV clinical proof pointHigh impact
The August 6 earnings release reported first clinical biopsy evidence of direct cccDNA elimination in PBGENE-HBV, including a 1-log reduction with less than 1% remaining in one patient, while additional PBGENE-HBV updates are targeted for year-end 2026 [#SEC-8K-2026-08-06].
2026-12-31eventPBGENE-DMD recruitment and data milestoneHigh impact
Multiple sites are actively recruiting for the Phase 1/2 FUNCTION-DMD trial, with PBGENE-DMD clinical updates targeted for year-end 2026 [#SEC-8K-2026-08-06].
2026-12-31catalystBinary clinical execution and timing riskHigh impact
The next major repricing remains dependent on limited-patient clinical data and year-end updates; delay, weak durability, safety concerns, or disappointing efficacy could overwhelm the runway and platform-validation positives.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology